
Wybierz swoją etykietę
widoczna od razu na fiolceTorasemid
Medication
- Wysyłka z Niemiec
Zamówienie
- DHL ze śledzeniem
- Dyskretne opakowanie
W skrócie
Torasemid w liczbach
Najważniejsze dane z naszego leksykonu. Przeciągnij punkt wzdłuż krzywej, aby zobaczyć, ile zostaje po jednej dawce, według obliczeń.
Pełny wpis w leksykonieHow long does it stay in the body?
Share left after one dose, calculated with a half-life of ~3.5 hours
Simplified model without an absorption phase, half-life from the TPD lexicon. The lexicon gives 3 to 4 hours, we calculate with the middle.
Half-life
about3to4hours
duration 6 to 8 hours
- Class
- Loop diureticNKCC2 inhibitor
- Use
- Oral1x daily in the morning
- Sizes
- 10 mg1 size in the shop
What studies show
All 5 sources in the lexiconTorsemide vs furosemide after discharge in heart failure (TRANSFORM-HF) (opens in a new tab)
Mentz et al., JAMA, 2023Torasemide in chronic heart failure - results of the TORIC study (opens in a new tab)
Cosín & Díez, European Journal of Heart Failure, 2002- Vargo et al., Clinical Pharmacology & Therapeutics, 1995
Dla Torasemid nie ma jeszcze analizy laboratoryjnej. ZagłosujZleć test samodzielnie, zapłacimy połowęWszystkie analizy laboratoryjne
Wiedza
Wszystko o Torasemid
Szczegółowe informacje wkrótce.
Is torsemide approved?
Yes. ChEMBL lists torsemide with phase 4 as the highest phase and first approval in 1993. ClinicalTrials.gov lists 56 trials with torsemide, as of 26 October 2026.
What did TRANSFORM-HF show?
2,859 patients received torsemide or furosemide after a hospital stay for heart failure. 26.1 versus 26.2 percent died, without difference. Death or hospital stay within 12 months did not differ significantly either (47.3 versus 49.3 percent).
How does absorption differ from furosemide?
Torsemide has a bioavailability of about 80 percent in healthy people, furosemide 26 to 65 percent. In heart failure the peak level was reached after 1.1 instead of 2.4 hours. Absorption varied less.
Why did earlier trials see an advantage?
An open trial with 234 patients found fewer hospital stays for heart failure (17 versus 32 percent). The TORIC observation with 1,377 patients saw lower mortality (2.2 versus 4.5 percent) but was not randomised. The larger randomised trial did not confirm this.
What about potassium?
In TORIC 12.9 percent on torsemide had low potassium at the end, 17.9 percent on furosemide or other diuretics. The groups were not randomised.
Do liver and kidney matter?
Torsemide is mainly broken down in the liver, only about 20 percent appear unchanged in the urine. In liver disease clearance fell to about half. In kidney failure total clearance stayed largely the same according to the review.
Powiązane
Podobne produkty
Telmisartan
Leki · Układ sercowo-naczyniowy Układ sercowo-naczyniowy
2 rozmiary
Testowane w laboratorium
Ivermectin
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Fenbendazol
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Prednisone
Leki · Żołądek i wątroba Żołądek i wątroba
1 rozmiar
Torasemid